These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 22433711

  • 1. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
    Zhang XH, Shin JY, Kim JO, Oh JE, Yoon SA, Jung CK, Kang JH.
    Cancer Lett; 2012 Sep 28; 322(2):213-22. PubMed ID: 22433711
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.
    Cancer Res; 2009 Aug 15; 69(16):6515-21. PubMed ID: 19638574
    [Abstract] [Full Text] [Related]

  • 3. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F.
    Clin Cancer Res; 2010 Oct 15; 16(20):4990-5001. PubMed ID: 20810384
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY, Xu YP, Jin W, Lou LG.
    Anticancer Drugs; 2012 Aug 15; 23(7):698-705. PubMed ID: 22441567
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X.
    Cancer Chemother Pharmacol; 2007 Feb 15; 59(2):183-95. PubMed ID: 16724239
    [Abstract] [Full Text] [Related]

  • 6. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I, Kói K, Horváth O, Cserepes M, Molnár D, Izsák V, Dobos J, Hegedűs B, Tóvári J, Tímár J.
    Oncotarget; 2016 Nov 29; 7(48):79503-79514. PubMed ID: 27780929
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, Eizenberg O, Zamir G, Izhar U, Shapira OM, Peled A, Wald O.
    J Thorac Cardiovasc Surg; 2012 Nov 29; 144(5):1167-1175.e1. PubMed ID: 22925564
    [Abstract] [Full Text] [Related]

  • 8. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 9. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S, Yang W, Wang Y, Ou W, Ma Q, Yu C, Ren J, Zhong G, Shi H, Yuan Z, Su X, Zhu W.
    Int J Mol Med; 2013 Jan 15; 31(1):33-42. PubMed ID: 23128378
    [Abstract] [Full Text] [Related]

  • 10. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.
    Cancer Chemother Pharmacol; 2008 Sep 15; 62(4):621-9. PubMed ID: 18038274
    [Abstract] [Full Text] [Related]

  • 11. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
    Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F.
    Oncotarget; 2016 Jan 26; 7(4):4265-78. PubMed ID: 26673006
    [Abstract] [Full Text] [Related]

  • 12. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.
    Invest New Drugs; 2015 Feb 26; 33(1):12-21. PubMed ID: 25342139
    [Abstract] [Full Text] [Related]

  • 13. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice.
    Lin YJ, Zhen YS.
    Anticancer Drugs; 2009 Jan 26; 20(1):65-72. PubMed ID: 19343002
    [Abstract] [Full Text] [Related]

  • 14. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
    Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N.
    J Clin Oncol; 2010 Apr 10; 28(11):1835-42. PubMed ID: 20212250
    [Abstract] [Full Text] [Related]

  • 15. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
    Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, Perego P, Zuco V, Orlandi A, Passeri D, Carminati P, Cavazza C, Zunino F.
    Clin Cancer Res; 2010 Aug 01; 16(15):3944-53. PubMed ID: 20562210
    [Abstract] [Full Text] [Related]

  • 16. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L, Zhou Y, Li Y, Zhou J, Wu Y, Cui Y, Yang G, Hong Y.
    Cancer Lett; 2015 Feb 28; 357(2):520-6. PubMed ID: 25499080
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
    Kobayashi M, Sonobe M, Takahashi T, Yoshizawa A, Ishikawa M, Kikuchi R, Okubo K, Huang CL, Date H.
    Anticancer Res; 2011 Dec 28; 31(12):4619-23. PubMed ID: 22199339
    [Abstract] [Full Text] [Related]

  • 18. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
    Gao ZQ, Han BH, Sha HF, Shi ZY, Yang XH, Feng JX.
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr 28; 33(4):284-8. PubMed ID: 20646461
    [Abstract] [Full Text] [Related]

  • 19. [Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo].
    Zhou YL, Hu WX, Lü YP, Qiu LN, Wang WS, Yang ZY, Liu JD, Rao GW.
    Yao Xue Xue Bao; 2007 Jan 28; 42(1):26-34. PubMed ID: 17520803
    [Abstract] [Full Text] [Related]

  • 20. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Jiang Y, Li C, Ma Y, Chen J, Li Y, Chen L.
    Clin Lab; 2012 Jan 28; 58(5-6):551-61. PubMed ID: 22783588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.